Benitec Biopharma Inc.
BNTC · XNASCIK 1808898fmd_0SDZHNQ09H3855DXY1253T3CG7Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2018 to Jun 30, 2026, 29 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 12 | 0 | 0 | 0 | 0 | 0 | – | – |
| Research and development | 5 | 3 | 7 | 11 | 13 | 16 | 18 | 23 |
| Total operating expenses | 10 | 8 | 14 | 18 | 19 | 22 | 42 | 51 |
| Operating income | 3 | (8) | (14) | (18) | (19) | (22) | (42) | (51) |
| Other non-operating income (expense) | 0 | 0 | (0) | (0) | (0) | 1 | 4 | 6 |
| Income before taxes | 3 | (8) | 2 | (18) | (20) | (22) | (38) | (46) |
| Income tax expense | – | – | – | – | – | – | – | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | (46) |
| Net income | 3 | (8) | (14) | (18) | (20) | (22) | (38) | (46) |
| Net income to common shareholders | – | – | – | – | (20) | (22) | (38) | (46) |